Department of Dermatology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.
Department of Dermatology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.
J Am Acad Dermatol. 2017 Apr;76(4):745-753.e19. doi: 10.1016/j.jaad.2016.12.004. Epub 2017 Feb 4.
Janus kinase (JAK) inhibitors are emerging as a promising new treatment modality for many inflammatory conditions.
Our aim was to systematically review the available data on the use of JAK inhibitors in cutaneous diseases.
This is a systematic review of PubMed and ClinicalTrials.gov.
One hundred thirty-four articles matched our search terms, of which 78 were original articles and 12 reports on adverse events. Eighteen clinical trials were found. JAK inhibitors have been extensively studied for psoriasis, showing beneficial results that were comparable to the effects achieved by etanercept. Favorable results were also observed for alopecia areata. Promising preliminary results were reported for vitiligo, dermatitis, graft versus host disease, cutaneous T cell lymphoma, and lupus erythematosus. The most common adverse events reported were infections, mostly nasopharyngitis and upper respiratory tract infections.
It was not possible to perform a meta-analysis of the results.
This systematic review shows that while JAK inhibitors hold promise for many skin disorders, there are still gaps regarding the correct dosing and safety profile of these medications for dermatologic indications. Additional trials are necessary to address these gaps.
Janus 激酶 (JAK) 抑制剂作为许多炎症性疾病的一种有前途的新治疗方法正在出现。
我们旨在系统地回顾 JAK 抑制剂在皮肤疾病中的应用的现有数据。
这是对 PubMed 和 ClinicalTrials.gov 的系统回顾。
有 134 篇文章符合我们的搜索条件，其中 78 篇是原始文章，12 篇是关于不良反应的报告。发现了 18 项临床试验。JAK 抑制剂已广泛研究用于银屑病，显示出与依那西普相当的疗效。斑秃也观察到了良好的结果。白癜风、皮炎、移植物抗宿主病、皮肤 T 细胞淋巴瘤和红斑狼疮也有初步的良好结果报告。报告的最常见不良事件是感染，主要是鼻咽炎和上呼吸道感染。
不可能对结果进行荟萃分析。
这项系统综述表明，虽然 JAK 抑制剂为许多皮肤疾病带来了希望，但对于皮肤科适应症，这些药物的正确剂量和安全性仍存在差距。需要进一步的试验来解决这些差距。
